Patents by Inventor Joshua O. Ojwang

Joshua O. Ojwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Guanosine-rich oligonucleotide integrase inhibitors
    Patent number: 6355785
    Abstract: A method and compositions for treating viral infection (IV) vitro and in vivo using a guanosine-rich oligonucleotide. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity and integrase inhibition activity.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: March 12, 2002
    Assignee: Aronex Pharmaceuticals, Inc.
    Inventors: Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Ojwang, Michael E. Hogan, Yves Pommier, Abhijit Mazumder
  • Anti-viral guanosine-rich oligonucleotides and method of treating HIV
    Patent number: 6323185
    Abstract: A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotide. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity and integrase inhibition activity.
    Type: Grant
    Filed: July 17, 1996
    Date of Patent: November 27, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Ojwang, Michael E. Hogan
  • Anti-viral guanosine-rich oligonucleotides
    Patent number: 6150339
    Abstract: A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. They can be composed of at least about 40% guanosine nucleotides. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: November 21, 2000
    Assignee: Aronex Pharmaceuticals, Inc.
    Inventors: Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Ojwang, Michael E. Hogan
  • Retroviral vectors comprising an anti-hiv or other nucleic acid
    Patent number: 6132962
    Abstract: This invention provides an infectious retrovirus having inserted between the 5' and 3' long terminal repeat sequences of the retrovirus a nucleic acid encoding an anti-HIV-type specific agent or a foreign nucleic acid under the control of a pol III promoter. Host cells containing the retroviral vectors of this invention also are provided. Further provided are methods of interfering with or preventing HIV viral replication in a cell infected with HIV or likely to be infected with HIV.
    Type: Grant
    Filed: June 16, 1997
    Date of Patent: October 17, 2000
    Assignee: The Regents of the University of California
    Inventors: Flossie Wong-Staal, Mang Yu, Osamu Yamada, Joshua O. Ojwang, Markley C. Leavitt, Anthony Ho
  • HIV-specific ribozymes
    Patent number: 5811275
    Abstract: This invention provides an infectious retrovirus having inserted between the 5' and 3' long terminal repeat sequences of the retrovirus a nucleic acid encoding an anti-HIV-type specific agent under the control of a pol III promoter. Host cells containing the retroviral vectors of this invention also are provided. Further provided are methods of interfering with or preventing HIV viral replication in a cell infected with HIV or likely to be infected with HIV.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 22, 1998
    Assignee: The Regents of the University of California
    Inventors: Flossie Wong-Staal, Mang Yu, Osamu Yamada, Joshua O. Ojwang, Mark Leavitt, Anthony Ho
  • HIV-specific ribozymes
    Patent number: 5670361
    Abstract: This invention provides an infectious retrovirus having inserted between the 5' and 3' long terminal repeat sequences of the retrovirus a nucleic acid encoding an anti-HIV-type specific agent under the control of a pol III promoter. Host cells containing the retroviral vectors of this invention also are provided. Further provided are methods of interfering with or preventing HIV viral replication in a cell infected with HIV or likely to be infected with HIV.
    Type: Grant
    Filed: May 17, 1994
    Date of Patent: September 23, 1997
    Assignee: The Regents of the University of California
    Inventors: Flossie Wong-Staal, Mang Yu, Osamu Yamada, Joshua O. Ojwang, Markley C. Leavitt, Anthony Ho
  • Anti-viral guanosine-rich oligonucleotides
    Patent number: 5567604
    Abstract: A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides are composed of at least about 50% guanosine nucleotides. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity.
    Type: Grant
    Filed: October 28, 1993
    Date of Patent: October 22, 1996
    Assignee: Aronex Pharmaceuticals, Inc.
    Inventors: Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Ojwang